OBJECTIVE: Examine changes in SARS-CoV-2 seropositivity before and during the national vaccination campaign in the Czech Republic. DESIGN: Prospective national population-based cohort study. SETTING: Masaryk University, RECETOX, Brno. PARTICIPANTS: 22 130 persons provided blood samples at two time points approximately 5-7 months apart, between October 2020 and March 2021 (phase I, before vaccination), and between April and September 2021 (during vaccination campaign). OUTCOME MEASURES: Antigen-specific humoral immune response was analysed by detection of IgG antibodies against the SARS-CoV-2 spike protein by commercial chemiluminescent immunoassays. Participants completed a questionnaire that included personal information, anthropometric data, self-reported results of previous RT-PCR tests (if performed), history of symptoms compatible with COVID-19 and records of COVID-19 vaccination. Seroprevalence was compared between calendar periods, previous RT-PCR results, vaccination and other individual characteristics. RESULTS: Before vaccination (phase I), seroprevalence increased from 15% in October 2020 to 56% in March 2021. By the end of phase II, in September 2021, prevalence increased to 91%; the highest seroprevalence was seen among vaccinated persons with and without previous SARS-CoV-2 infection (99.7% and 97.2%, respectively), while the lowest seroprevalence was found among unvaccinated persons with no signs of disease (26%). Vaccination rates were lower in persons who were seropositive in phase I but increased with age and body mass index. Only 9% of unvaccinated subjects who were seropositive in phase I became seronegative by phase II. CONCLUSIONS: The rapid increase in seropositivity during the second wave of the COVID-19 epidemic (covered by phase I of this study) was followed by a similarly steep rise in seroprevalence during the national vaccination campaign, reaching seropositivity rates of over 97% among vaccinated persons.

Department of Epidemiology and Public Health University College London London WC1E 6BT UK

Health Insurance Company of the Ministry of the Interior of the Czech Republic Prague Czech Republic

Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic

QualityLab Association Prague Czech Republic

RECETOX Faculty of Science Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Arora RK, Joseph A, Van Wyk J, et al. . SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. Lancet Infect Dis 2021;21:e75–6. 10.1016/S1473-3099(20)30631-9 PubMed DOI PMC

Vaughan A, Duffell EF, Friedl GS, et al. . Seroprevalence of SARS-CoV-2 antibodies prior to the widespread introduction of vaccine programmes in the WHO european region, january - december 2020: a systematic review. Epidemiology 2021. 10.1101/2021.12.02.21266897 PubMed DOI PMC

Ward H, Whitaker M, Flower B, et al. . Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat Commun 2022;13:907. 10.1038/s41467-022-28527-x PubMed DOI PMC

Siller A, Seekircher L, Wachter GA, et al. . Seroprevalence, waning and correlates of anti-SARS-CoV-2 IgG antibodies in Tyrol, Austria: large-scale study of 35,193 blood donors conducted between june 2020 and september 2021. Viruses 2022;14:568. 10.3390/v14030568 PubMed DOI PMC

Stringhini S, Zaballa M-E, Pullen N, et al. . Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in geneva, switzerland, 1 june to 7 july 2021. Euro Surveill 2021;26:2100830. 10.2807/1560-7917.ES.2021.26.43.2100830 PubMed DOI PMC

Whitaker HJ, Elgohari S, Rowe C, et al. . Impact of COVID-19 vaccination program on seroprevalence in blood donors in england, 2021. J Infect 2021;83:237–79. 10.1016/j.jinf.2021.04.037 PubMed DOI PMC

Soeorg H, Jõgi P, Naaber P, et al. . Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination. Infect Dis (Lond) 2022;54:63–71. 10.1080/23744235.2021.1974540 PubMed DOI PMC

Piler P, Thon V, Andrýsková L, et al. . Nationwide increases in anti-SARS-cov-2 IgG antibodies between october 2020 and march 2021 in the unvaccinated Czech population. Commun Med (Lond) 2022;2:19. 10.1038/s43856-022-00080-0 PubMed DOI PMC

Rostami A, Sepidarkish M, Leeflang MMG, et al. . SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect 2021;27:331–40. 10.1016/j.cmi.2020.10.020 PubMed DOI PMC

Bobrovitz N, Arora RK, Cao C, et al. . Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis. PLOS ONE 2021;16:e0252617. 10.1371/journal.pone.0252617 PubMed DOI PMC

Grant R, Dub T, Andrianou X, et al. . SARS-CoV-2 population-based seroprevalence studies in europe: a scoping review. BMJ Open 2021;11:e045425. 10.1136/bmjopen-2020-045425 PubMed DOI PMC

Rothman KJ, Greenland S, Lash TL. Modern epidemiology. Philadelphia PA: Lippincott Williams & Wilkins, 2008.

Hall V, Foulkes S, Insalata F. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med 2022;386:1207–20. 10.1056/NEJMoa2118691 PubMed DOI PMC

Siller A, Wachter GA, Neururer S, et al. . Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020. Wien Klin Wochenschr 2021;133:1272–80. 10.1007/s00508-021-01963-3 PubMed DOI PMC

Jones JM, Stone M, Sulaeman H, et al. . Estimated us infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, july 2020-may 2021. JAMA 2021;326:1400–9. 10.1001/jama.2021.15161 PubMed DOI PMC

Russell MW, Moldoveanu Z, Ogra PL, et al. . Mucosal immunity in COVID-19: a neglected but critical aspect of SARS-CoV-2 infection. Front Immunol 2020;11:611337. 10.3389/fimmu.2020.611337 PubMed DOI PMC

Bergeri I, Lewis HC, Subissi L, et al. . Early epidemiological investigations: World Health organization unity protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic. Influenza Other Respir Viruses 2022;16:7–13. 10.1111/irv.12915 PubMed DOI PMC

Long-Term Immunological Alertness and Response to COVID-19 Vaccination-Conditions for Prevention in Early Palliative Oncological Care Patients